Effects in The ApoB/ApoA-I ratio Using Rosuvastatin and atorvastatin in patients with acute coronary syndrome
Study identifier:D3560L00052
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Comparison of the Effects Noted in The ApoB/ApoA-I ratio Using Rosuvastatin and atorvastatin in patients with acUte coronary Syndrome - CENTAURUS
Medical condition
Acute Coronary Syndrome
Phase
Phase 3
Healthy volunteers
No
Study drug
Rosuvastatin, Atorvastatin
Sex
All
Actual Enrollment
1160
Study type
Interventional
Age
18 Years - 75 Years
Date
Study Start Date: 01 Jan 2006
Primary Completion Date: -
Study Completion Date: 01 Oct 2007
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
AstraZeneca France Medical Director
AstraZeneca
